logo
Share SHARE
FONT-SIZE Plus   Neg

EpiCept's AmiKet Receives FDA's Fast Track Designation

EpiCept Corp. (EPCT.PK) on Tuesday said its late-stage topical analgesic cream AmiKet has been granted fast track designation by the U.S. Food and Drug Administration.

The product is to treat neuropathic pain associated with chemotherapy-induced peripheral neuropathy, or CIPN, in patients previously treated with taxane-based chemotherapy.

The FDA's fast track program is designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and address unmet medical needs.

Products with such a designation often receive priority review, which may reduce the standard review time by half. The designation also allows for more frequent interactions with the FDA during the drug development process.

Jack Talley, President and Chief Executive Officer of EpiCept, said, "We believe the FDA Fast Track designation is confirmation of the pressing need for therapies to treat neuropathic pain associated with CIPN."

EpiCept had previously announced the engagement of SunTrust Robinson Humphrey to assist in exploring strategic alternatives to maximize the commercial opportunity of AmiKet. The engagement will focus on the identification and implementation of a strategy to optimize AmiKet's value for the company's stockholders.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
ConAgra Foods Inc. (CAG) reported a net income attributable to the company for the fourth quarter ended May 29, 2016 that declined 43.8 percent from last year. Adjusted earnings per share from continuing operations decreased 5% from the prior year. The comparable earnings per share decline reflected... Another busy month on the FDA calendar has gone by but not without its fair share of hurrahs and heartaches. This is not unexpected, given the uncertainties characterizing drug development and approval processes, which in turn manifest as volatility in stocks belonging to the biotech space. German sporting goods giant Adidas Group (ADDYY.PK, ADDDF.PK) extended its long-term relationship with rapper and fashion designer Kanye West, launching a new line of Yeezy brand products for all genders, the company stated. adidas + Kanye West offers Yeezy branded footwear, apparel and accessories for all genders. Under the deal, West will join with adidas team to lead the development...
comments powered by Disqus
Follow RTT